Opinion|Videos|February 3, 2025
Summary and Closing Remarks
Key Takeaways
- Biomarkers, including genetic mutations and protein expressions, are vital for predicting disease progression and treatment response.
- Advanced diagnostic techniques are essential for identifying molecular and cellular indicators that inform patient prognosis.
Panelists summarize the key points discussed regarding the evolving landscape of IgA nephropathy treatments, highlighting the importance of addressing unmet needs, the significance of reducing proteinuria, and the role of emerging therapies in modifying disease progression, ultimately emphasizing the necessity for personalized treatment approaches and effective communication with patients to improve clinical outcomes.
Advertisement
Episodes in this series
- Thanks to you all for this rich and informative discussion. Before we conclude, I’d like to get final thoughts from you.
Advertisement
Related to this article
Reena Mehra, MD, discusses a post hoc analysis in which AD109 reduced AHI4 by 59.6% in postmenopausal women vs 44.0% in non-menopausal participants.
Advertisement
Advertisement
Trending on HCPLive
1
RAINIER: Povetacicept Cuts Proteinuria, Gd-IgA1 in IgA Nephropathy
2
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
3
Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD
4
IMAgINATION: Sefaxersen Meets Phase 3 Proteinuria Endpoint in IgA Nephropathy
5